Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients

Transfusion

Volumn 54, Issue 5, 2014, Pages 1243-1250

  Varmavuo, Ville ^a   Rimpiläinen, Johanna ^b,c   Kuitunen, Hanne ^c   Nihtinen, Anne ^d   Vasala, Kaija ^e   Mikkola, Maija ^f,g   Kutila, Anu ^f   Lehtonen, Päivi ^h   Kuittinen, Taru ^a   Mäntymaa, Pentti ⁱ   Nousiainen, Tapio ^a   Kuittinen, Outi ^c   Jantunen, Esa ^a,j  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^e Central Finland Central Hospital   (Finland)

^f MIKKELI CENTRAL HOSPITAL   (Finland)

^g PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^h Savonlinna Central Hospital   (Finland)

ⁱ Laboratory of Eastern Finland   (Finland)

^j UNIVERSITY OF EASTERN FINLAND   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; MESNA; MITOXANTRONE; PLERIXAFOR; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; VINCRISTINE; VINDESINE;

ABDOMINAL BLEEDING; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BRAIN HEMORRHAGE; BURKITT LYMPHOMA; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; ENGRAFTMENT; EVENING DOSAGE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GRAFT INFECTION; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; INFLUENZA A (H1N1); LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; T CELL LYMPHOMA; THROMBOCYTE COUNT;

ADULT; AGED; ANTIGENS, CD34; CELL SEPARATION; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84900513642     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12434     Document Type: Article

References (43)

1. Ljungman P, Bregni M, Brune M, et al.; European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
2. Jantunen E, Sureda A,. The evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transplant 2012; 18: 660-673.
3. Baldomero H, Gratwohl M, Gratwohl A, et al.; European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485-501.
4. DiPersio JF, Micallef IN, Stiff PJ, et al.; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
5. Jantunen E, Lemoli RM,. Preemptive use of plerixafor in difficult-to-mobilize patients: An emerging concept. Transfusion 2012; 52: 906-914.
6. Kuittinen T, Nousiainen T, Halonen P, et al. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-912. (Pubitemid 38660123)
7. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
8. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.
9. Jantunen E, Varmavuo V, Juutilainen A, et al. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol 2012; 91: 1073-1079.
10. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-820. (Pubitemid 36410987)
11. Sugrue MW, Williams K, Pollock BH, et al. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509-519. (Pubitemid 32162390)
12. Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 2007; 40: 111-118. (Pubitemid 47046208)
13. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719-724.
14. Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506-512.
15. Wang S, Nademanee A, Qian D, et al. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion 2007; 47: 2207-2216. (Pubitemid 350151197)
16. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
17. Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155. (Pubitemid 28193863)
18. Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-972. (Pubitemid 34845951)
19. Jantunen E, Fruehauf S,. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011; 46: 627-635.
20. Fruehauf S, Tricot G,. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol Blood Marrow Transplant 2010; 16: 1629-1648.
21. Varmavuo V, Mäntymaa P, Kuittinen T, et al. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion 2012; 52: 1785-1791.
22. Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012; 89: 128-135.
23. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874. (Pubitemid 41208607)
24. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
25. D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-363.
26. Jantunen E, Penttilä K, Pyörälä M, et al. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2011; 46: 308-309.
27. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338. (Pubitemid 351330727)
28. DiPersio JF, Stadtmauer EA, Nademanee A, et al.; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
29. Jantunen E, Kuittinen T, Mahlamäki E, et al. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: A single centre experience. Eur J Haematol 2011; 86: 299-304.
30. Moreb JS, Salmasinia D, Hsu J, et al. Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients. Adv Hematol 2011; 2011: 517561.
31. Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 315-318. (Pubitemid 46408198)
32. Alexander ET, Towery JA, Miller AN, et al. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and day +100 hematopoietic graft function. Transfusion 2011; 51: 1995-2000.
33. Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-412. (Pubitemid 351398642)
34. Kroschinsky F, Hölig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417-1423. (Pubitemid 44117972)
35. Putkonen M, Rauhala A, Pelliniemi T, et al. Single dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: A case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 2009; 88: 673-680.
36. Costa LJ, Kramer C, Hogan KR, et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012; 52: 2375-2381.
37. Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49: 1890-1900.
38. Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009; 11: 992-1001.
39. Taubert I, Saffrich R, Zepeda-Moreno A, et al. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 2011; 13: 459-466.
40. DiPersio JF, Ho AD, Hanrahan J, et al. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011; 17: 943-955.
41. Fruehauf S, Ehninger G, Hübel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-275.
42. Geisler CH, Kolstad A, Laurell A, et al.; Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
43. Sabloff M, Atkins HL, Bence-Bruckler I, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13: 956-964. (Pubitemid 47055389)